Gas Chromatographic-mass Spectrometric Analysis of Perillyl Alcohol and Metabolites in Plasma
Overview
Authors
Affiliations
Perillyl alcohol (POH), a metabolite of d-limonene and a component of the lavender oil, is currently in Phase I clinical trials both as a chemopreventative and chemotherapeutic agent. In vivo, POH is metabolized to less active perillic acid (PA) and cis- and trans-dihydroperillic acids [DHPA, 4-(1'-methylethenyl)-cyclohexane-1-carboxylic acid]. Previous pharmacokinetic studies using a GC-MS method detected POH metabolites but not POH itself; thus these studies lacked information on the parent drug. The present report describes a sensitive GC-MS method for the quantitation of POH and metabolites using stable-isotopically labeled internal standards. The residue obtained from CH2Cl2 extraction of a plasma sample was silylated. The products were separated on a capillary column and analyzed by an ion-trap GC-MS using NH3 chemical ionization. POH-d3 was used as the internal standard for POH while 13C-PA-d2 was used as the internal standards for the metabolites. The quantitation limits for POH, PA, cis- and trans-DPA were <10 ng/ml using 1-2 ml plasma. The assay was validated in rat and human plasma. The assay was linear from 2 to 2000 ng/ml for POH, 10 to 1000 ng/ml for PA and trans-DHPA, and 20 to 1000 ng/ml for cis-DHPA monitored. The within-run and between-run coefficients of variation were all <8%. Preliminary pharmacokinetic data from a rat following i.v. administration of POH at 23 mg/kg and from a patient receiving POH at 500 mg/m2 p.o. was also provided. Intact POH, PA, cis- and trans-DHPA were all detected in plasma in both cases. Two new major metabolites were found in human and one in the rat plasma.
Antioxidant, Anti-Inflammatory, and Anticancer Activities of Five Citrus Peel Essential Oils.
Li Y, Li W, Ye Z, Ji C, Zhou Z Antioxidants (Basel). 2025; 13(12.
PMID: 39765890 PMC: 11672981. DOI: 10.3390/antiox13121562.
The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers.
Chen T, da Fonseca C, Levin D, Schonthal A Pharmaceutics. 2021; 13(12).
PMID: 34959448 PMC: 8709132. DOI: 10.3390/pharmaceutics13122167.
Nehra G, Andrews S, Rettig J, Gould M, Haag J, Howard S Sci Rep. 2021; 11(1):6351.
PMID: 33737566 PMC: 7973779. DOI: 10.1038/s41598-021-85293-4.
Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development.
Chen T, da Fonseca C, Schonthal A Int J Mol Sci. 2018; 19(12).
PMID: 30563210 PMC: 6321279. DOI: 10.3390/ijms19123905.
Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.
Chen T, da Fonseca C, Schonthal A Am J Cancer Res. 2015; 5(5):1580-93.
PMID: 26175929 PMC: 4497427.